Revolution Picks Up Remains Of EQRx In All-Stock Deal
Deal Aimed At Beefing Up Balance Sheet
Revolution Medicines is looking to pump the $1bn it will get from the acquisition into its RAS inhibitor pipeline, with trials planned to start in 2024.
Revolution Medicines is looking to pump the $1bn it will get from the acquisition into its RAS inhibitor pipeline, with trials planned to start in 2024.